Trials / Completed
CompletedNCT01403948
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to investigate the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics and efficacy of BI 836826 monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma with at least prior treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 836826 | Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2017-11-14
- Completion
- 2018-02-28
- First posted
- 2011-07-27
- Last updated
- 2020-08-11
- Results posted
- 2020-08-11
Locations
12 sites across 3 countries: France, Germany, South Korea
Source: ClinicalTrials.gov record NCT01403948. Inclusion in this directory is not an endorsement.